H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Crinetics to $69 from $60 and keeps a Buy rating on the shares. The firm says that given the strength of the dataset from the PATHFNDR-1 and -2 studies, it sees little risk of approval and the company may be able to launch paltusotine by the end of 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Crinetics Pharmaceuticals CFO Marc Wilson Resigns
- Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
- Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
- Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 3 Best Stocks to Buy Now, 7/10/2024, According to Top Analysts